The Experimental Therapeutics Clinical Trials Network (ETCTN) Lead Academic Organizations (UM1 Clinical Trial Required)
- Response deadline
- Jun 30, 2026 Closed
- Date posted
- May 8, 2026
- Source
- Open notice
Description
Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits applications from institutions/organizations that propose to maintain or establish Lead Academic Organizations (LAOs) as part of the NCI Experimental Therapeutics Clinical Trials Network (ETCTN). ETCTN LAOs will design, develop, monitor, conduct, and analyze early phase clinical trials (e.g., phase 0, phase 1, phase 2, pilot, and other experimental therapeutic clinical trials) involving agents under regulatory sponsorship for New Investigational Drug (IND) applications held by NCI's Division of Cancer Treatment and Diagnosis (DCTD), Cancer Therapy Evaluation Program (CTEP). Each ETCTN LAO will participate in clinical trials it leads as well as clinical trials led by other LAOs in the network.
Classifications
- NAICS93.395
Documents (1)
- DownloadRFA-CA-27-016-Full-Announcement.htmltext/html;charset=UTF-8181 KB
Contacts
Similar contracts
- HEAL Initiative: Non-addictive Analgesic Therapeutics Development [Small Molecules and Biologics] to Treat Pain (UG3/UH3 Clinical Trial Optional)Due Feb 20, 2029
- Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)Due Oct 19, 2026
- INCLUDE Project: Clinical Trials Phased Awards for Down syndrome Research (R61/R33 Clinical Trial Required)Due Jun 15, 2028
- The Experimental Therapeutics Clinical Trials Network (ETCTN) Pharmacokinetic Resource Laboratory (U24 Clinical Trial Not Allowed)Due Jun 30, 2026
- Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional)Due Jul 5, 2029
- Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed)Due Jan 7, 2028